{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:12:44Z","timestamp":1779207164389,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Patients with metastatic clear cell renal cell carcinoma (ccRCC) are often treated with immunotherapy (ICI), with no definitive biomarkers of response.\n                      <jats:italic>ARID1A<\/jats:italic>\n                      is mutated among ICI responders in several cancer types, including ccRCC. Immunohistochemistry (IHC) is a widely available method of detecting ARID1A protein levels. Assessment of tumor infiltrating immune cells (TILs) also has been linked to ICI response in some studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We explored the expression of ARID1A protein using IHC (manual and QuPath) in a cohort of 29 patients with metastatic ccRCC who had undergone cytoreductive nephrectomy (CRN). We correlated ARID1A expression with clinicopathological data, survival, and TILs. We corroborated our IHC results in 488 cases from the TCGA-KIRC dataset, and utilized immune deconvolution platforms to define changes in TILs in relation to ARID1A in TCGA-KIRC and an ICI-therapy validation cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low ARID1A protein expression is associated with large tumor size, lymphovascular invasion, high stage, low TILS, and worse overall survival. Low ARID1A mRNA in TCGA-KIRC similarly had significantly worse survival and were immune cold histologically and in ESTIMATE immune score. xCell showed significant enrichment of Th1, Th2, myeloid dendritic cells, macrophages, and T NK cells in low ARID1A mRNA ccRCC with elevation of Tregs in tumors that have high ARID1A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Low ARID1A expression (protein and mRNA) is a marker of poor prognosis in ccRCC, and is associated with shorter survival and reduced TILs, but immune cells linked to ICI response are increased offering an immune advantage to ARID1A\n                      <jats:sup>Low<\/jats:sup>\n                      patients who receive ICI therapy. ARID1A IHC provides comparable results to bulk mRNA analysis, suggesting that it can be reliably used to explore ARID1A as a potential ICI biomarker in ccRCC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-025-04166-8","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:12:23Z","timestamp":1767492743000},"page":"2345-2359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Loss of ARID1A expression is associated with worse survival and reduced tumor infiltrating lymphocytes in advanced clear cell renal cell carcinoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Mohamed Ashraf","family":"Mansour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshmi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiz","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterini","family":"Boleti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine Gia Binh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4661-1563","authenticated-orcid":false,"given":"Soha","family":"El-Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"4166_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4166_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11:79\u201387. https:\/\/doi.org\/10.14740\/wjon1279.","journal-title":"World J Oncol"},{"key":"4166_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.euo.2019.04.007","volume":"2","author":"A Larcher","year":"2019","unstructured":"Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Mejean A, et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur Urol Oncol. 2019;2:365\u201378. https:\/\/doi.org\/10.1016\/j.euo.2019.04.007.","journal-title":"Eur Urol Oncol"},{"key":"4166_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","volume":"20","author":"M Rosellini","year":"2023","unstructured":"Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol. 2023;20:133\u201357. https:\/\/doi.org\/10.1038\/s41585-022-00676-0.","journal-title":"Nat Rev Urol"},{"key":"4166_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-020-00296-6","volume":"10","author":"M Zhou","year":"2021","unstructured":"Zhou M, Yuan J, Deng Y, Fan X, Shen J. Emerging role of SWI\/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. Oncogenesis. 2021;10:1\u20138. https:\/\/doi.org\/10.1038\/s41389-020-00296-6.","journal-title":"Oncogenesis"},{"key":"4166_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313\u2013326.e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.075.","journal-title":"Cell Rep"},{"key":"4166_CR7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359:801\u20136. https:\/\/doi.org\/10.1126\/science.aan5951.","journal-title":"Science"},{"key":"4166_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2019.37.7_suppl.666","volume":"37","author":"AA Hakimi","year":"2019","unstructured":"Hakimi AA, Ged Y, Flynn J, Hoen DR, Di Natale RG, Blum KA, et al. The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB). JCO. 2019;37:666\u2013666. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.666.","journal-title":"JCO"},{"key":"4166_CR9","doi-asserted-by":"publisher","first-page":"12226","DOI":"10.1096\/fj.201802720RR","volume":"33","author":"K Somsuan","year":"2019","unstructured":"Somsuan K, Peerapen P, Boonmark W, Plumworasawat S, Samol R, Sakulsak N, et al. ARID1A knockdown triggers epithelial\u2013mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma. FASEB J. 2019;33:12226\u201339. https:\/\/doi.org\/10.1096\/fj.201802720RR.","journal-title":"FASEB J"},{"key":"4166_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38:803\u2013817.e4. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.011.","journal-title":"Cancer Cell"},{"key":"4166_CR11","doi-asserted-by":"publisher","first-page":"1136248","DOI":"10.3389\/fonc.2023.1136248","volume":"13","author":"B Fontana","year":"2023","unstructured":"Fontana B, Gallerani G, Salamon I, Pace I, Roncarati R, Ferracin M. ARID1A in cancer: friend or foe? Front Oncol. 2023;13:1136248. https:\/\/doi.org\/10.3389\/fonc.2023.1136248.","journal-title":"Front Oncol"},{"key":"4166_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/15384047.2021.2011643","volume":"23","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Yan C, Wang X, Xu Z, Lv J, Xu X, et al. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. Cancer Biol Ther. 2022;23:104\u201311. https:\/\/pubmed.ncbi.nlm.nih.gov\/35239432\/.","journal-title":"Cancer Biol Ther"},{"key":"4166_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/jpm12010113","volume":"12","author":"J Hwang","year":"2022","unstructured":"Hwang J, Kim H, Han J, Lee J, Hong S, Kim S, et al. Identification of survival-specific genes in clear cell renal cell carcinoma using a customized next-generation sequencing gene panel. J Pers Med. 2022;12:113. https:\/\/doi.org\/10.3390\/jpm12010113.","journal-title":"J Pers Med"},{"key":"4166_CR14","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1158\/0008-5472.CAN-12-0656","volume":"72","author":"AH Girgis","year":"2012","unstructured":"Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 2012;72:5273\u201384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0656.","journal-title":"Cancer Res"},{"key":"4166_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ajpath.2013.01.007","volume":"182","author":"Z Lichner","year":"2013","unstructured":"Lichner Z, Scorilas A, White NMA, Girgis AH, Rotstein L, Wiegand KC, et al. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol. 2013;182:1163\u201370. https:\/\/doi.org\/10.1016\/j.ajpath.2013.01.007.","journal-title":"Am J Pathol"},{"key":"4166_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.humpath.2014.12.002","volume":"46","author":"JH Park","year":"2015","unstructured":"Park JH, Lee C, Suh JH, Chae JY, Kim HW, Moon KC. Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma. Hum Pathol. 2015;46:454\u201360. https:\/\/doi.org\/10.1016\/j.humpath.2014.12.002.","journal-title":"Hum Pathol"},{"key":"4166_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cjp2.103","volume":"4","author":"S Khalique","year":"2018","unstructured":"Khalique S, Naidoo K, Attygalle AD, Kriplani D, Daley F, Lowe A, et al. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. J Pathol Clin Res. 2018;4:154\u201366. https:\/\/doi.org\/10.1002\/cjp2.103.","journal-title":"J Pathol Clin Res"},{"key":"4166_CR18","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41379-020-0592-2","volume":"33","author":"YP Hung","year":"2020","unstructured":"Hung YP, Redig A, Hornick JL, Sholl LM. ARID1A mutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis. Mod Pathol. 2020;33:2256\u201368. https:\/\/doi.org\/10.1038\/s41379-020-0592-2.","journal-title":"Mod Pathol"},{"key":"4166_CR19","doi-asserted-by":"publisher","first-page":"e53931","DOI":"10.1371\/journal.pone.0053931","volume":"8","author":"X Zhang","year":"2013","unstructured":"Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia B, et al. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PLoS ONE. 2013;8:e53931. https:\/\/doi.org\/10.1371\/journal.pone.0053931.","journal-title":"PLoS ONE"},{"key":"4166_CR20","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960\u20134. https:\/\/doi.org\/10.1126\/science.1129139.","journal-title":"Science"},{"key":"4166_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer. 2018;17:129. https:\/\/doi.org\/10.1186\/s12943-018-0864-3.","journal-title":"Mol Cancer"},{"key":"4166_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun DA, Hou Y, Bakouny Z, Ficial M, Sant\u2019 Angelo M, Forman J, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26:909\u201318. https:\/\/doi.org\/10.1038\/s41591-020-0839-y.","journal-title":"Nat Med"},{"key":"4166_CR23","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5.","journal-title":"Sci Rep"},{"key":"4166_CR24","unstructured":"TCGA\u2014PanCanAtlas Publications | NCI Genomic Data Commons. (n.d.). https:\/\/gdc.cancer.gov\/about-data\/publications\/pancanatlas. Accessed 1 Sept 2024."},{"key":"4166_CR25","unstructured":"Digital Slide Archive (DSA), Digital Slide Archive (DSA). (n.d.). https:\/\/cancer.digitalslidearchive.org\/. Accessed 1 July 2024."},{"key":"4166_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00346-1","volume":"7","author":"K El Bairi","year":"2021","unstructured":"El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, et al. The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7:1\u201317. https:\/\/doi.org\/10.1038\/s41523-021-00346-1.","journal-title":"NPJ Breast Cancer"},{"key":"4166_CR27","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"key":"4166_CR28","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307.","journal-title":"Cancer Res"},{"key":"4166_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12.","journal-title":"Methods Mol Biol"},{"key":"4166_CR30","doi-asserted-by":"publisher","first-page":"e1142","DOI":"10.1002\/cti2.1142","volume":"9","author":"M Tamminga","year":"2020","unstructured":"Tamminga M, Hiltermann TJN, Schuuring E, Timens W, Fehrmann RS, Groen HJ. Immune microenvironment composition in non-small cell lung cancer and its association with survival. Clin Transl Immunol. 2020;9:e1142. https:\/\/doi.org\/10.1002\/cti2.1142.","journal-title":"Clin Transl Immunol"},{"key":"4166_CR31","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdz287","volume":"30","author":"R Dienstmann","year":"2019","unstructured":"Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, et al. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II\/III colorectal cancer. Ann Oncol. 2019;30:1622\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdz287.","journal-title":"Ann Oncol"},{"key":"4166_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-0716-0327-7_19","volume":"2120","author":"D Aran","year":"2020","unstructured":"Aran D. Cell-type enrichment analysis of bulk transcriptomes using xCell. Methods Mol Biol. 2020;2120:263\u201376. https:\/\/doi.org\/10.1007\/978-1-0716-0327-7_19.","journal-title":"Methods Mol Biol"},{"key":"4166_CR33","unstructured":"Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data\u2014PMC. (n.d.). https:\/\/www-ncbi-nlm-nih-gov.libproxy.ucl.ac.uk\/pmc\/articles\/PMC5718706\/. Accessed 10 Sept 2024."},{"key":"4166_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00262-018-2150-z","volume":"67","author":"F Finotello","year":"2018","unstructured":"Finotello F, Trajanoski Z. Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol Immunother. 2018;67:1031\u201340. https:\/\/doi.org\/10.1007\/s00262-018-2150-z.","journal-title":"Cancer Immunol Immunother"},{"key":"4166_CR35","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1038\/s41379-021-00864-0","volume":"34","author":"O Br\u00fcck","year":"2021","unstructured":"Br\u00fcck O, Lee MH, Turkki R, Uski I, Penttil\u00e4 P, Paavolainen L, et al. Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. Mod Pathol. 2021;34:2229\u201341. https:\/\/doi.org\/10.1038\/s41379-021-00864-0.","journal-title":"Mod Pathol"},{"key":"4166_CR36","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41467-020-15959-6","volume":"11","author":"X-D Liu","year":"2020","unstructured":"Liu X-D, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020;11:2135. https:\/\/doi.org\/10.1038\/s41467-020-15959-6.","journal-title":"Nat Commun"},{"key":"4166_CR37","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/cancers11040470","volume":"11","author":"V Kouck\u00fd","year":"2019","unstructured":"Kouck\u00fd V, Bou\u010dek J, Fialov\u00e1 A. Immunology of plasmacytoid dendritic cells in solid tumors: a brief review. Cancers. 2019;11:470. https:\/\/doi.org\/10.3390\/cancers11040470.","journal-title":"Cancers"},{"key":"4166_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal JA, Per\u00e1n M, Giovannetti E. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024;17:44. https:\/\/doi.org\/10.1186\/s13045-024-01559-0.","journal-title":"J Hematol Oncol"},{"key":"4166_CR39","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","volume":"187","author":"MB Maxwell","year":"2024","unstructured":"Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, et al. ARID1A suppresses R-loop mediated STING-Type I interferon pathway activation of anti-tumor immunity. Cell. 2024;187:3390\u20133408.e19. https:\/\/doi.org\/10.1016\/j.cell.2024.04.025.","journal-title":"Cell"},{"key":"4166_CR40","doi-asserted-by":"publisher","first-page":"7946","DOI":"10.3390\/ijms24097946","volume":"24","author":"CU Monjaras-Avila","year":"2023","unstructured":"Monjaras-Avila CU, Lorenzo-Leal AC, Luque-Badillo AC, D\u2019Costa N, Chavez-Mu\u00f1oz C, Bach H. The tumor immune microenvironment in clear cell renal cell carcinoma. Int J Mol Sci. 2023;24:7946. https:\/\/doi.org\/10.3390\/ijms24097946.","journal-title":"Int J Mol Sci"},{"key":"4166_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei Y, Wei X. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15:61. https:\/\/doi.org\/10.1186\/s13045-022-01282-8.","journal-title":"J Hematol Oncol"},{"key":"4166_CR42","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature"},{"key":"4166_CR43","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, Pellegry CM, et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat Cancer. 2024;5:1607\u201321. https:\/\/doi.org\/10.1038\/s43018-024-00830-0.","journal-title":"Nat Cancer"},{"key":"4166_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10020-020-00208-9","volume":"26","author":"D Sun","year":"2020","unstructured":"Sun D, Tian L, Zhu Y, Wo Y, Liu Q, Liu S, et al. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer. Mol Med. 2020;26:78. https:\/\/doi.org\/10.1186\/s10020-020-00208-9.","journal-title":"Mol Med"},{"key":"4166_CR45","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7150\/jca.41296","volume":"11","author":"T Jiang","year":"2020","unstructured":"Jiang T, Chen X, Su C, Ren S, Zhou C. Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes. J Cancer. 2020;11:776\u201380. https:\/\/doi.org\/10.7150\/jca.41296.","journal-title":"J Cancer"},{"key":"4166_CR46","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1002\/imm3.70001","volume":"1","author":"X Ke","year":"2025","unstructured":"Ke X, Li K, Lin A, Qian Y, Luo P. FastUKB: a revolutionary tool for simplifying UK Biobank data analysis. iMetaMed. 2025;1:e70001. https:\/\/doi.org\/10.1002\/imm3.70001.","journal-title":"iMetaMed"},{"key":"4166_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cpan.2024.12.001","volume":"21","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhao Y, Zhang L. Emerging trends and hot topics in the application of multi-omics in drug discovery: a bibliometric and visualized study. Curr Pharm Anal. 2024;21:20\u201332. https:\/\/doi.org\/10.1016\/j.cpan.2024.12.001.","journal-title":"Curr Pharm Anal"},{"key":"4166_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpan.2024.11.001","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Lin A, Luo P. Advancing pharmaceutical research: a comprehensive review of cutting-edge tools and technologies. Curr Pharm Anal. 2024;21:1\u201319. https:\/\/doi.org\/10.1016\/j.cpan.2024.11.001.","journal-title":"Curr Pharm Anal"},{"key":"4166_CR49","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1002\/imm3.70002","volume":"1","author":"K Li","year":"2025","unstructured":"Li K, Zhang Y, Qian Y, Qin H, Zhang H, Li C, et al. Tumor electrophysiology in precision tumor therapy. iMetaMed. 2025;1:e70002. https:\/\/doi.org\/10.1002\/imm3.70002.","journal-title":"iMetaMed"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04166-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04166-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04166-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:31Z","timestamp":1779204751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04166-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4166"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04166-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the ethical standards as outlined in the 1964 Declaration of Helsinki and its later amendments.\u00a0The West of Scotland Research Ethics Committee provided ethical approval for this study (REC reference 16\/WS\/0039; IRAS Project ID: 196635). Informed consent for participation in this study was waived by the West of Scotland Research Ethics Committee, because this retrospective observational study uses anonymized clinical data and historically archived excess tissue from previous clinical diagnosis, and the risk of participation in the study was not greater than the minimum risk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}